leisure time -WSS

leisure time

author：leisure time 2025-09-27 23:51:49 - browse：74

Are biotech’s dog days over? What’s a PIPE? And what can unseat Wegovy?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We dive into the the latest craze in the world of biotech finance, involving hedge funds and some insider information, and explain why not everyone thinks it’s such a good idea. We also discuss a banner month for biotech stocks and the latest twist in obesity research.

For more on what we cover, here’s more on PIPEs; here’s the news from Viking Therapeutics; here’s the latest in MASH; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： European regulators recommend Amylyx's ALS drug be rejected

entertainment

WSS

Burning questions for the 2024 JPM Healthcare Conference

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Peter Marks talks Operation Warp Speed for Rare Diseases

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

New weight loss drugs work. But how can they best be used?

How clinical AI models' predictive power can degrade over time

knowledge

leisure time

leisure time

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Burning questions for the 2024 JPM Healthcare Conference

23andMe had bad news about my health. I wish a person had delivered it

How should state employee insurance handle Wegovy?

The high cost of giving birth even with insurance

How doctors and nurses shape Google's AI

Dobbs anniversary: the lost opportunity of abortion as health care

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The biotech scorecard for Q1: 17 stock

entertainment

Eight reasons why you should get an updated Covid vaccine

Cancer cells are shown to suck energy source from immune cells

Life sciences deals on track to hit lowest point since 2017

How doctors and nurses shape Google's AI

Peter Marks talks Operation Warp Speed for Rare Diseases

JPM: CVS says Medicare Advantage patients are impacting profits

entertainment

focus

entertainment

leisure time